{"id":968,"date":"2017-09-21T13:55:07","date_gmt":"2017-09-21T13:55:07","guid":{"rendered":"https:\/\/malmed.gov.mk\/?page_id=968"},"modified":"2020-01-22T14:21:14","modified_gmt":"2020-01-22T14:21:14","slug":"%d0%be%d1%81%d0%bd%d0%be%d0%b2%d0%bd%d0%b8-%d0%b8%d0%bd%d1%84%d0%be%d1%80%d0%bc%d0%b0%d1%86%d0%b8%d0%b8-%d0%b7%d0%b0-%d1%84%d0%b0%d1%80%d0%bc%d0%b0%d0%ba%d0%be%d0%b2%d0%b8%d0%b3%d0%b8%d0%bb%d0%b0","status":"publish","type":"page","link":"https:\/\/malmed.gov.mk\/sq\/%d0%be%d1%81%d0%bd%d0%be%d0%b2%d0%bd%d0%b8-%d0%b8%d0%bd%d1%84%d0%be%d1%80%d0%bc%d0%b0%d1%86%d0%b8%d0%b8-%d0%b7%d0%b0-%d1%84%d0%b0%d1%80%d0%bc%d0%b0%d0%ba%d0%be%d0%b2%d0%b8%d0%b3%d0%b8%d0%bb%d0%b0\/","title":{"rendered":"Informacione themelore p\u00ebr Farmakovigjilenc\u00ebn"},"content":{"rendered":"<p>Mir\u00ebsevini n\u00eb  Web \u2013 faqen e Agjencis\u00eb s\u00eb Barnave dhe Pajisjeve Mjek\u00ebsore n\u00eb Republik\u00ebn e Maqedonis\u00eb s\u00eb Veriut (MALMED) n\u00eb pjes\u00ebn q\u00eb ka t\u00eb b\u00ebj\u00eb me&nbsp;<strong>(FARMAKOVIGJILENC\u00cbN<\/strong>.<\/p>\n<p><strong>Farmakovigjilenca <\/strong>p\u00ebrfaq\u00ebson shkenc\u00eb dhe p\u00ebrmbledhje t\u00eb aktiviteteve q\u00eb lidhen me zbulimin, vler\u00ebsimin, kuptimin, parandalimin dhe qasjen n\u00eb rast t\u00eb reaksioneve t\u00eb pad\u00ebshiruara t\u00eb barnave si dhe informacione t\u00eb reja p\u00ebr rreziqet prej p\u00ebrdorimit t\u00eb barnave.<\/p>\n<p>Informacionet p\u00ebr kualitetin,  efikasitetin dhe sigurin\u00eb e barnave merren prej faz\u00ebs paraklinike dhe klinike gjat\u00eb zhvillimit t\u00eb barnave. \n  Informacionet e siguris\u00eb p\u00ebr barnat, t\u00eb marra nga studimet klinike jan\u00eb t\u00eb kufizuara, sepse burojn\u00eb prej p\u00ebrdorimit t\u00eb saj n\u00eb kushte specifike dhe rrept\u00ebsisht t\u00eb kontrolluara t\u00eb definuara n\u00eb  protokolin e studimeve klinike. N\u00eb  periudh\u00ebn e  post-marketingut  merren informacione p\u00ebr efikasitetin dhe sigurin\u00eb  e barnave nga p\u00ebrdorimi i tij n\u00eb popullat\u00eb n\u00eb p\u00ebrditshm\u00ebrin\u00eb n\u00eb praktik\u00ebn sh\u00ebndet\u00ebsore. Gjat\u00eb k\u00ebsaj periudhe merren informacione p\u00ebr p\u00ebrdorimin e barnave n\u00eb  popullat\u00ebn specifike t\u00eb pacient\u00ebve (pacient\u00ebt geriatrik\u00eb, pacient\u00ebt pediatrik\u00eb, grat\u00eb  shtatz\u00ebna, n\u00ebnat infermiere, etj.), nd\u00ebrsa plot\u00ebsuese n\u00eb k\u00ebt\u00eb periudh\u00eb identifikohen Informacionet p\u00ebr kualitetin,  efikasitetin dhe sigurin\u00eb e barnave merren prej faz\u00ebs paraklinike dhe klinike gjat\u00eb zhvillimit t\u00eb barnave.Informacionet e siguris\u00eb p\u00ebr barnat, t\u00eb marra nga studimet klinike jan\u00eb t\u00eb kufizuara, sepse burojn\u00eb prej p\u00ebrdorimit t\u00eb saj n\u00eb kushte specifike dhe rrept\u00ebsisht t\u00eb kontrolluara t\u00eb definuara n\u00eb  protokolin e studimeve klinike. N\u00eb  periudh\u00ebn e  post-marketingut  merren informacione p\u00ebr efikasitetin dhe sigurin\u00eb  e barnave nga p\u00ebrdorimi i tij n\u00eb popullat\u00eb n\u00eb p\u00ebrditshm\u00ebrin\u00eb n\u00eb praktik\u00ebn sh\u00ebndet\u00ebsore. Gjat\u00eb k\u00ebsaj periudhe merren informacione p\u00ebr p\u00ebrdorimin e barnave n\u00eb  popullat\u00ebn specifike t\u00eb pacient\u00ebve (pacient\u00ebt geriatrik\u00eb, pacient\u00ebt pediatrik\u00eb, grat\u00eb  shtatz\u00ebna, n\u00ebnat infermiere, etj.), nd\u00ebrsa plot\u00ebsuese n\u00eb k\u00ebt\u00eb periudh\u00eb identifikohen rrall\u00eb efektet an\u00ebsore.<\/p>\n<p><strong>Farmakovigjilenca luan rrol t\u00eb r\u00ebnd\u00ebsish\u00ebm n\u00eb  moniterimin e siguris\u00eb te t\u00eb gjitha barnat dhe mbrojtjen e sh\u00ebndetit publik. <\/strong><\/p>\n<p>MALMED \u00ebsht\u00eb p\u00ebrgjegj\u00ebse p\u00ebr monitorimin e reaksioneve t\u00eb pad\u00ebshiruara t\u00eb barnave n\u00eb Republik\u00ebn e Maqedonis\u00eb s\u00eb Veriut. MALMED k\u00ebto aktivitete i siguron p\u00ebrmes Qendr\u00ebs Komb\u00ebtare t\u00eb Farmakovigjilenc\u00ebs, e cila \u00ebsht\u00eb pjes\u00eb p\u00ebrb\u00ebr\u00ebse e saj.<br>\nAgjencia e themelon dhe vazhdimisht e p\u00ebrmir\u00ebson, azhurnon dhe p\u00ebrparon Sistemin Komb\u00ebtar p\u00ebr Farmakovigjilenc\u00eb. Ky sistem mund\u00ebson zbulimin e sinjaleve t\u00eb siguris\u00eb, identifikimin e rreziqeve prej p\u00ebrdorimit t\u00eb barnave, kategorizimin e tyre, vler\u00ebsimin, minimizimin, komunikimin dhe parandalimin, me q\u00ebllim q\u00eb t\u00eb sigurohet raporti m\u00eb i mir\u00eb i mundsh\u00ebm i p\u00ebrfitimit\/ rrezikut p\u00ebr barnat n\u00eb praktik\u00ebn e p\u00ebrditshme dhe promovimin e recetave racionale dhe sigurt p\u00ebrshkrimin e barnave.<\/p>\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>\u0414\u043e\u0431\u0440\u0435\u0434\u043e\u0458\u0434\u043e\u0432\u0442\u0435 \u043d\u0430 \u0432\u0435\u0431-\u0441\u0442\u0440\u0430\u043d\u0430\u0442\u0430 \u043d\u0430 \u0410\u0433\u0435\u043d\u0446\u0438\u0458\u0430\u0442\u0430 \u0437\u0430 \u043b\u0435\u043a\u043e\u0432\u0438 \u0438 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438 \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u0430 \u043d\u0430 \u0420\u0435\u043f\u0443\u0431\u043b\u0438\u043a\u0430 \u041c\u0430\u043a\u0435\u0434\u043e\u043d\u0438\u0458\u0430 (\u041c\u0410\u041b\u041c\u0415\u0414) \u0432\u043e \u0434\u0435\u043b\u043e\u0442 \u043a\u043e\u0458 \u0441\u0435 \u043e\u0434\u043d\u0435\u0441\u0443\u0432\u0430 \u043d\u0430&nbsp;\u0424\u0410\u0420\u041c\u0410\u041a\u041e\u0412\u0418\u0413\u0418\u041b\u0410\u041d\u0426\u0410. \u0424\u0430\u0440\u043c\u0430\u043a\u043e\u0432\u0438\u0433\u0438\u043b\u0430\u043d\u0446\u0430 \u043f\u0440\u0435\u0442\u0441\u0442\u0430\u0432\u0443\u0432\u0430 \u043d\u0430\u0443\u043a\u0430 \u0438 \u0437\u0431\u0438\u0440 \u043d\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438 \u043f\u043e\u0432\u0440\u0437\u0430\u043d\u0438 \u0441\u043e \u043e\u0442\u043a\u0440\u0438\u0432\u0430\u045a\u0435, \u043f\u0440\u043e\u0446\u0435\u043d\u0430, \u0440\u0430\u0437\u0431\u0438\u0440\u0430\u045a\u0435, \u043f\u0440\u0435\u0432\u0435\u043d\u0446\u0438\u0458\u0430 \u0438 \u043f\u043e\u0441\u0442\u0430\u043f\u0443\u0432\u0430\u045a\u0435 \u0432\u043e \u0441\u043b\u0443\u0447\u0430\u0458 \u043d\u0430 \u043d\u0435\u0441\u0430\u043a\u0430\u043d\u0438 \u0440\u0435\u0430\u043a\u0446\u0438\u0438 \u043e\u0434 \u043b\u0435\u043a\u043e\u0432\u0438\u0442\u0435, \u043a\u0430\u043a\u043e \u0438 \u043d\u043e\u0432\u0438 \u0438\u043d\u0444\u043e\u0440\u043c\u0430\u0446\u0438\u0438 \u0437\u0430 \u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u0438\u0442\u0435 \u043e\u0434 \u0443\u043f\u043e\u0442\u0440\u0435\u0431\u0430 \u043d\u0430 \u043b\u0435\u043a\u043e\u0432\u0438\u0442\u0435. \u0418\u043d\u0444\u043e\u0440\u043c\u0430\u0446\u0438\u0438\u0442\u0435 \u0437\u0430 \u043a\u0432\u0430\u043b\u0438\u0442\u0435\u0442\u043e\u0442, [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-968","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/pages\/968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/comments?post=968"}],"version-history":[{"count":0,"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/pages\/968\/revisions"}],"wp:attachment":[{"href":"https:\/\/malmed.gov.mk\/sq\/wp-json\/wp\/v2\/media?parent=968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}